Gallic Acid Induces T-helper-1-like T Cells and Strengthens Immune Checkpoint Blockade Efficacy
Overview
Oncology
Pharmacology
Authors
Affiliations
Background: Foxp3 regulatory T (T) cells facilitate tumor immune evasion by forming a suppressive tumor microenvironment. Therefore, immune therapies promoting T fragility may greatly enhance immune checkpoint blockade (ICB) efficacy in cancers.
Methods: We have screened 2640 compounds and identified the gut microbial metabolite gallic acid, which promotes Foxp3 degradation and T instability by repressing gene transcription. In vivo and in vitro experiments have been performed to explore the roles of Usp21 in T cells. Importantly, we treated tumor-bearing mice with gallic acid and anti-PD-1 antibody to explore the potential therapeutic value of gallic acid in clinical cancer immunotherapy.
Results: Mechanistically, gallic acid prevents STAT3 phosphorylation and the binding of phosphorylated STAT3 to gene promoter. The deubiquitinated Usp21 and stabilized PD-L1 proteins boost the function of T cells. Combination of gallic acid and anti-PD-1 antibody, in colorectal cancer (CRC) treatment, not only significantly dampen T cell function by impairing PD-L1/PD-1 signaling and downregulating Foxp3 stability, but also promote CD8 T cells' production of IFN-γ and limited tumor growth.
Conclusion: Our findings have implications for improving the efficacy of ICB therapy in CRC by inducing T-helper-1-like Foxp3 T cells.
Advanced RPL19-TRAP-seq method reveals mechanism of action of bioactive compounds.
Zhu D, Hu J, Tan R, Lin X, Wang R, Lu J Nat Prod Bioprospect. 2025; 15(1):16.
PMID: 40042546 PMC: 11882491. DOI: 10.1007/s13659-025-00500-3.
Gut microbiota in cancer initiation, development and therapy.
Zhang R, Zhang X, Lau H, Yu J Sci China Life Sci. 2025; .
PMID: 39821827 DOI: 10.1007/s11427-024-2831-x.
The SUMO Family: Mechanisms and Implications in Thyroid Cancer Pathogenesis and Therapy.
Jiaerken B, Liu W, Zheng J, Qu W, Wu Q, Ai Z Biomedicines. 2024; 12(10).
PMID: 39457720 PMC: 11505470. DOI: 10.3390/biomedicines12102408.
Zhou Z, Zheng J, Lu Y, Mai Z, Lin Y, Lin P Exp Hematol Oncol. 2024; 13(1):103.
PMID: 39438986 PMC: 11495118. DOI: 10.1186/s40164-024-00575-7.
Yang Q, Duan B, Yue J, Zhang D, Chen X, Shi M Front Immunol. 2024; 15:1444222.
PMID: 39346920 PMC: 11428109. DOI: 10.3389/fimmu.2024.1444222.